Riik: Lõuna-Aafrika Vabariik
keel: inglise
Allikas: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
CEFACIDAL 500 mg CEFACIDAL 1 g SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CEFACIDAL 500 mg CEFACIDAL 1 g Powder for injection COMPOSITION: Cefazolin Sodium equivalent to Cefazolin 500 mg or 1 g activity. PHARMACOLOGICAL CLASSIFICATION A 20.1.1 - Broad spectrum antibiotic. PHARMACOLOGICAL ACTION CEFACIDAL (cefazolin sodium) is a broad-spectrum bactericidal, semi-synthetic cephalosporin for parenteral administration. Chemically cefazolin is the sodium salt of 7-[1-(1H)-tetrazolylacetamide]- 3-[2-(5-methyl-1,3,4- thiadiazolyl)-thiomethyl]-delta³-cephem- 4-carboxylic acid. CEFACIDAL given intravenously or intramuscularly produces notably high serum levels. Serum binding occurs at a rate of 74%. Cefazolin is resistant to degradation in the body, is virtually not inactivated in the liver, and is primarily excreted in the urine unchanged. Following intramuscular injection of cefazolin 500 mg, 63+17% of the dose was recovered within 6 hours and approximately 80% to 100% within 24 hours. Peak urine concentrations of approximately 1000 micrograms/mL and 4000 micrograms/mL are achieved after intramuscular administration of 500 mg and 1 g doses, respectively. When cefazolin is administered to patients with unobstructed biliary tracts, high concentrations well over serum levels occur in the gallbladder tissue and bile. In the presence of obstruction, however, concentration in the bile is considerably lower than the serum level. Tissue distribution of cefazolin is greatest in the kidney, liver and lungs. The concentration of cefazolin in the joint space when the synovial membrane is inflammed is comparable to the concentration found in the serum due to the ease with which the antibiotic crosses the inflammed membrane. CEFACIDAL is bactericidal against a wide range of gram-positive and g Lugege kogu dokumenti